1. GIH Clinical Research Update: 2004–2005
Michael Camilleri 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 12, Pages (December 2005)
DOI: /S (05)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Effect of intragastric, endoscopically deployed balloon on weight (wt) loss in patients with obesity: Trial design as a flow chart (upper panel) and weight loss (lower panel). Note that the 2 treatment arms show similar degrees of weight loss during a 2-year period, and that an additive effect of the balloon over dietary and behavioral treatment could not be demonstrated. Rx, prescription. Reprinted, from Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005;61:19–27, with permission from the American Society for Gastrointestinal Endoscopy.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Effect of the entire spectrum of different forms of bariatric surgery on weight (wt) loss (upper panel) and on comorbidities related to obesity (lower panel). In the upper panel, % XS wt loss refers to the percentage of excess weight loss (weight loss/excess weight) × 100, where excess weight = total preoperative weight minus ideal weight. Reprinted with permission from Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737. Copyright © American Medical Association. All rights reserved.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Histologic features of serrated adenoma in association with familial colorectal cancer (CRC) and discordance in microsatellite instability. Reprinted from Young J, Barker MA, Simms LA, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005;3:254–263, with permission from the American Gastroenterological Association.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
Duke’s classification of colorectal cancers identified in Olmsted County, MN, among patients undergoing screening vs symptomatic patients (upper panel). Note the downward shift in staging is associated with improved overall survival (lower panel). Reprinted from Gupta AK, Melton LJ 3rd, Petersen GM, et al. Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study. Clin Gastroenterol Hepatol 2005;3:150–158, with permission from the American Gastroenterological Association.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
Stellate cells (arrow) associated with hepatic fibrosis in patients with NAFLD. Reprinted from Feldstein AE, Papouchado BG, Angulo P, et al. Hepatic stellate cells and fibrosis progression in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005;3:384–389, with permission from the American Gastroenterological Association.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions